SOLUTIONS MADE REAL
DEAD

Serial Number

86130555

Owner

LABCORP DRUG DEVELOPMENT INC.

Attorney

William M. Bryner

Filing Date

Nov 27, 2013

Add to watchlist:

No watchlists yet
View on USPTO

SOLUTIONS MADE REAL Trademark

Serial Number: 86130555 • Registration: 4654201

SOLUTIONS MADE REAL is a trademark filed by LABCORP DRUG DEVELOPMENT INC. on November 27, 2013. The trademark is classified under Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

LABCORP DRUG DEVELOPMENT INC. (26 trademarks)

210 CARNEGIE CENTER
PRINCETON, NJ 085406233

Entity Type: 03

COVANCE INC. (60 trademarks)

210 Carnegie Center
Princeton, NJ 085406233

Entity Type: 03

Trademark Details

Filing Date

November 27, 2013

Registration Date

December 9, 2014

Published for Opposition

April 22, 2014

Cancellation Date

June 20, 2025

Goods & Services

Providing a database featuring information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices

Business management, business strategy, business consultancy and advisory services for the pharmaceutical, medical device, food and healthcare industries; market research, namely, collecting market trends data from providers and patients, data on health economic issues, and competitive intelligence data on the marketplace for pharmaceutical products and medical devices; regulatory submission management, namely, assisting others in preparing and filing applications with governmental regulatory bodies for approval of new drugs and medical devices; economic forecasting and analysis; administering customer service programs, namely, operating patient assistance programs for pharmaceutical products and medical devices, and providing access to advocacy groups and counseling for patients to promote patient satisfaction; information and advisory services relating to the foregoing

Scientific research and development; pharmaceutical drug development and testing services; research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; research and development of antibodies for in vitro and in vivo use; custom design and development of chemical reagents and biochemical assays; consulting services for others in the field of design, planning, and project management of scientific research, drug development, and clinical trials; medical and scientific research, namely, designing, organizing, conducting, and managing clinical trials for others; clinical research services, namely, collection, calibration, analysis and reporting of data in connection with clinical trials; scientific laboratory services; laboratory research services relating to pharmaceuticals, medical devices, biotechnology, biochemicals, antibodies, molecules for drug development, biomarker analysis, pharmacology, toxicology, drug metabolism, pharmacokinetics, biology, immunochemistry, health vaccines, pathology, and isotope chemistry; operating and maintaining a biorepository for medical and scientific research purposes; scientific research and analysis in the fields of biomarkers, genomics, proteomics, and genotyping; computer software design; development, updating and maintenance of software and databases; data mining; providing temporary use of on-line non-downloadable software for tracking, monitoring, analyzing, and reporting information and statistics in the fields of pharmaceutical and medical device development studies, clinical trials, patient reimbursement and insurance coverage, and biological research; food safety testing and consultation related thereto; scientific consulting and research services relating to food, food packaging, and nutritional chemistry; information and advisory services relating to the foregoing

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Jun 20, 2025 CAEX
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Dec 9, 2023 REM2
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 7, 2022 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 7, 2021 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 7, 2021 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 7, 2021 APRE
TEAS SECTION 8 & 15 RECEIVED
Dec 22, 2020 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 9, 2019 REM1
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 20, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 20, 2018 REAP
REGISTERED-PRINCIPAL REGISTER
Dec 9, 2014 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 1, 2014 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 31, 2014 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Oct 1, 2014 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 1, 2014 AITU
USE AMENDMENT FILED
Sep 17, 2014 IUAF
TEAS STATEMENT OF USE RECEIVED
Sep 17, 2014 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 17, 2014 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 22, 2014 NPUB
PUBLISHED FOR OPPOSITION
Apr 22, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2014 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2014 CNSA
ASSIGNED TO EXAMINER
Mar 12, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 11, 2013 NWOS
NEW APPLICATION ENTERED
Nov 30, 2013 NWAP